Evidence map›Paper›PMID 38230732›Full record

ArticleThe journal of prevention of Alzheimer's disease2024

Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets.

Y Salimi, D Domingo-Fernández, M Hofmann-Apitius, C Birkenbihl

Abstract read
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Encoding Discordance in the Alzheimer's Disease A/T/N Framework.medRxiv : the preprint server for health sciences · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Y SalimiYasamin Salimi and Colin Birkenbihl, Schloß Birlinghoven, Sankt Augustin 53757, Germany, yasamin.salimi@scai.fraunhofer.de; colin.birkenbihl@scai.fraunhofer.de.
D Domingo-Fernández
M Hofmann-Apitius
C Birkenbihl

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile the amyloid/tau/neurodegeneration (ATN) framework has found wide application in Alzheimer's disease research, it is unclear if thresholds obtained using distinct thresholding methods are concordant within the same dataset and interchangeable across cohorts.

objectivesTo investigate the robustness of data-driven thresholding methods and ATN profiling across cohort datasets. DESIGN AND

settingWe evaluated the impact of thresholding methods on ATN profiles by applying five commonly-used methodologies across cohort datasets. We assessed the generalizability of disease patterns discovered within ATN profiles by clustering individuals from different cohorts who were assigned to the same ATN profile. PARTICIPANTS AND MEASUREMENTS: Participants with available CSF amyloid-β 1-42, phosphorylated tau, and total tau measurements were included from eleven AD cohort studies.

resultsWe observed high variability among obtained ATN thresholds, both across methods and datasets that impacted the resulting profile assignments of participants significantly. Clustering participants from different cohorts within the same ATN category indicated that identified disease patterns were comparable across most cohorts and biases introduced through distinct thresholding and data representations remained insignificant in most ATN profiles. CONLUSION: Thresholding method selection is a decision of statistical relevance that will inevitably bias the resulting profiling and affect its sensitivity and specificity. Thresholds are likely not directly interchangeable between independent cohorts. To apply the ATN framework as an actionable and robust profiling scheme, a comprehensive understanding of the impact of used thresholding methods, their statistical implications, and a validation of results is crucial.

Indexed as

Alzheimer Diseasetau ProteinsAmyloid beta-PeptidesBiomarkersCohort StudiesHumansAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseaseATN frameworkbiomarker profilescohort studiesCSF thresholds

Identifiers

PMID38230732
PMCPMC10995057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.